<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23527251</article-id><article-id pub-id-type="pmc">3603865</article-id><article-id pub-id-type="publisher-id">PONE-D-12-28074</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0059692</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immunity</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group><subj-group><subject>Microbiology</subject><subj-group><subject>Immunity</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group><subj-group><subject>Bacterial Pathogens</subject></subj-group></subj-group><subj-group><subject>Model Organisms</subject><subj-group><subject>Animal Models</subject><subj-group><subject>Rat</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Immunity</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group><subj-group><subject>Clinical Research Design</subject><subj-group><subject>Animal Models of Disease</subject></subj-group></subj-group><subj-group><subject>Gastroenterology and Hepatology</subject><subj-group><subject>Liver Diseases</subject><subj-group><subject>Cirrhosis</subject></subj-group></subj-group></subj-group><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Bacterial Diseases</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Modulation of Inflammatory Response in a Cirrhotic Rat Model with Induced Bacterial Peritonitis</article-title><alt-title alt-title-type="running-head">Anti-TNF in Cirrhotic Rats with Peritonitis</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>S&#x000e1;nchez</surname><given-names>Elisabet</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Franc&#x000e9;s</surname><given-names>Rub&#x000e9;n</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Soriano</surname><given-names>Germ&#x000e1;n</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mirelis</surname><given-names>Beatriz</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sancho</surname><given-names>Francesc J.</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gonz&#x000e1;lez-Navajas</surname><given-names>Jos&#x000e9; Manuel</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mu&#x000f1;oz</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Xiao-yu</given-names></name><xref ref-type="aff" rid="aff9">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author" deceased="yes"><name><surname>P&#x000e9;rez-Mateo</surname><given-names>Miguel</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Such</surname><given-names>Jos&#x000e9;</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Guarner</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Liver Section, Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Centro de Investigaci&#x000f3;n Biom&#x000e9;dica en Red en el &#x000c1;rea tem&#x000e1;tica de Enfermedades Hep&#x000e1;ticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Institut dInvestigacions Biom&#x000e9;diques de Sant Pau (IIB), Barcelona, Spain</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Universitat Aut&#x000f2;noma de Barcelona, Bellaterra (Cerdanyola del Vall&#x000e8;s), Spain</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Department of Microbiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain</addr-line>
</aff><aff id="aff6">
<label>6</label>
<addr-line>Department of Pathology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain</addr-line>
</aff><aff id="aff7">
<label>7</label>
<addr-line>Unidad Hep&#x000e1;tica, Hospital General Universitario, Universidad Miguel Hern&#x000e1;ndez, Alicante, Spain</addr-line>
</aff><aff id="aff8">
<label>8</label>
<addr-line>Department of Microbiology, Hospital General Universitario, Universidad Miguel Hern&#x000e1;ndez, Alicante, Spain</addr-line>
</aff><aff id="aff9">
<label>9</label>
<addr-line>Research and Development Centocor, Malvern, Pennsylvania, United States of America</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Kaveri</surname><given-names>Srinivas</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Cordelier Research Center, INSERMU872-Team16, France</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>cguarner@santpau.cat</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>Centocor (Malvern, PA, USA) provided funding to conduct this investigation, and is the employer of XYS. The anti-TNF mAb used in this study is a product of Centocor. There are no further patents, products in development or marketed products to declare. This does not alter the authors&#x02019; adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: CG JS. Performed the experiments: ES RF FJS. Analyzed the data: ES RF GS BM FJS JS CG. Contributed reagents/materials/analysis tools: ES RF GS BM FJS JMG CM XYS MPM JS CG. Wrote the paper: ES CG JS RF.</p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>20</day><month>3</month><year>2013</year></pub-date><volume>8</volume><issue>3</issue><elocation-id>e59692</elocation-id><history><date date-type="received"><day>14</day><month>9</month><year>2012</year></date><date date-type="accepted"><day>17</day><month>2</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2013 S&#x000e1;nchez et al</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>S&#x000e1;nchez et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><p>Bacterial peritonitis is a severe complication in patients with cirrhosis and ascites and despite antibiotic treatment, the inflammatory response to infection may induce renal dysfunction leading to death. This investigation evaluated the effect of TNF-&#x003b1; blockade on the inflammatory response and mortality in cirrhotic rats with induced bacterial peritonitis treated or not with antibiotics. Sprague-Dawley rats with carbon-tetrachloride-induced cirrhosis were treated with an intraperitoneal injection of 10<sup>9</sup> CFU of <italic>Escherichia coli</italic> diluted in 20 mL of sterile water to induce bacterial peritonitis and randomized to receive subcutaneously-administered placebo, ceftriaxone, anti-TNF-&#x003b1; mAb and ceftriaxone, or anti-TNF-&#x003b1; mAb alone. No differences were observed between groups at baseline in respect to renal function, liver hepatic tests, serum levels of nitrite/nitrate and TNF-&#x003b1;. Treatment with ceftriaxone reduced mortality (73.3%) but differences did not reach statistical significance as compared to placebo. Mortality in rats treated with ceftriaxone and anti-TNF-&#x003b1; mAb was significantly lower than in animals receiving placebo (53% vs. 100%, p&#x0003c;0.01). Serum TNF-&#x003b1; decreased significantly in surviving rats treated with ceftriaxone plus anti-TNF-&#x003b1; mAb but not in treated with antibiotics alone. Additional studies including more animals are required to assess if the association of antibiotic therapy and TNF-&#x003b1; blockade might be a possible approach to reduce mortality in cirrhotic patients with bacterial peritonitis.</p></abstract><funding-group><funding-statement>This study was partially funded by unrestricted grants from the Generalitat de Catalunya (AGAUR) (2005SGR01085), Fondo de Investigaciones Sanitarias (FIS) PI08-0262 and from the Fundaci&#x000f3;n de Investigaci&#x000f3;n del Hospital General Universitario de Alicante. Centocor (Malvern, PA, USA) also provided funding to conduct this investigation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="5"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Spontaneous bacterial peritonitis (SBP) is a common and severe infection in patients with cirrhosis. Short-term prognosis has improved in recent decades due to prompt diagnosis during routine paracentesis <xref rid="pone.0059692-Guarner1" ref-type="bibr">[1]</xref>, standardization of diagnostic criteria based on ascitic fluid analyses <xref rid="pone.0059692-Rimola1" ref-type="bibr">[2]</xref>, <xref rid="pone.0059692-Runyon1" ref-type="bibr">[3]</xref>, and use of non-nephrotoxic third generation cephalosporins <xref rid="pone.0059692-Felisart1" ref-type="bibr">[4]</xref>. However, a significant number of patients with SBP still develop complications such as infections, systemic hemodynamic dysfunction and progressive renal failure, that lead to death <xref rid="pone.0059692-Guarner1" ref-type="bibr">[1]</xref>, <xref rid="pone.0059692-Rimola1" ref-type="bibr">[2]</xref>. Fifty percent of SBP patients who develop renal failure die during hospitalisation compared to only 6% of patients without this complication <xref rid="pone.0059692-Follo1" ref-type="bibr">[5]</xref>. The administration of albumin to these patients has demonstrated a reduction in the incidence of renal dysfunction and improvement in short-term survival <xref rid="pone.0059692-Follo1" ref-type="bibr">[5]</xref>, <xref rid="pone.0059692-Sort1" ref-type="bibr">[6]</xref>.</p><p>Episodes of SBP are associated with a marked release of proinflammatory cytokines such as tumour necrosis factor alpha (TNF-&#x003b1;) and effector molecules like nitric oxide metabolites (NOx) that keep a close relationship with SBP-induced morbidity and mortality <xref rid="pone.0059692-Navasa1" ref-type="bibr">[7]</xref>, <xref rid="pone.0059692-GarciaTsao1" ref-type="bibr">[8]</xref>. Patients with SBP show a long-lasting marked increase in serum NOx that may contribute to maintaining splanchnic vasodilatation and thus worsen the hemodynamic hyperkinetic state <xref rid="pone.0059692-Bories1" ref-type="bibr">[9]</xref>, <xref rid="pone.0059692-Genesca1" ref-type="bibr">[10]</xref>. Besides, nitrite and nitrate levels in serum and ascitic fluid at diagnosis of infection are significantly higher in SBP patients who develop renal impairment as a consequence of the ascitic fluid infection than in patients who maintain a stable renal function <xref rid="pone.0059692-Such1" ref-type="bibr">[11]</xref>.</p><p>Our group has recently reported that patients with SBP present recurrent episodes of bacterial translocation (BT) and maintain a marked inflammatory reaction <xref rid="pone.0059692-Frances1" ref-type="bibr">[12]</xref> despite the administration of third generation cephalosporins. In rats, a new therapy with the blockade of TNF-&#x003b1; has two direct consequences: it blunts the development of the hyperdynamic circulation and reduces portal pressure in a model of portal hypertension <xref rid="pone.0059692-LopezTalavera1" ref-type="bibr">[13]</xref>, and reduces the frequency of BT episodes in model of cirrhosis <xref rid="pone.0059692-Frances2" ref-type="bibr">[14]</xref>. Accordingly, the association of the usual third-generation cephalosporin with TNF-&#x003b1; blockade during a peritonitis episode may not only slow down the ongoing infection, but also improve survival. However, since TNF-&#x003b1; is part of the normal immune response, it is necessary to assess whether TNF-&#x003b1; blockade would increase the risk of developing superinfections.</p><p>We previously developed an experimental model of induced bacterial peritonitis in cirrhotic rats with or without ascites <xref rid="pone.0059692-Sanchez1" ref-type="bibr">[15]</xref> that mimics SBP in patients, and considered it might be useful to evaluate the efficacy of new therapeutic interventions on short-term prognosis of patients with SBP. The present study aimed, therefore, to evaluate the effect of TNF-&#x003b1; blockade on the inflammatory response and mortality in cirrhotic rats with induced bacterial peritonitis treated or not with antibiotics.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Animals</title><p>Male Sprague-Dawley were purchase from Harlan Laboratories. Rats were individually caged at a constant room temperature of 21&#x000b0;C, exposed to a 12&#x02236;12 light/dark cycle and allowed free access to water and rat chow.</p><p>The study was approved by the Animal Research Committee at the Institut de Recerca of Hospital de la Santa Creu i Sant Pau (Barcelona) and by the Department of Agriculture, Livestock and Fisheries of the Generalitat de Catalunya (DARP). Animals received care according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals.</p></sec><sec id="s2b"><title>Induction of Cirrhosis</title><p>Cirrhosis was induced as previously described by Runyon et al <xref rid="pone.0059692-Runyon2" ref-type="bibr">[16]</xref>. Rats weighing 100-120 g were fed standard rodent chow (B/K) and were treated with 1.5 mM/L phenobarbital in tap water. When rats reached a weight of 200 g weekly doses of carbon-tetrachloride (CCl<sub>4</sub>) (J.T. Baker Inc., Phillipsburg, NJ) were given intragastrically using a sterile pyrogen-free syringe (Artsana p.p.a., Greenclate) with an attached stainless steel animal feeding tube (Popper and Sons, New Hyde Park, NY) without anaesthesia. The first dose of CCl<sub>4</sub> was 20 &#x000b5;L and subsequent doses were adjusted based on changes in weight 48 hours after the last dose, as previously reported <xref rid="pone.0059692-Runyon3" ref-type="bibr">[17]</xref>.</p></sec><sec id="s2c"><title>Experimental Design</title><p>CCl<sub>4</sub> was administered over 16 weeks, the required period for cirrhosis development <xref rid="pone.0059692-Runyon2" ref-type="bibr">[16]</xref>. To rule out the presence of ascites a paracentesis was performed under air anaesthesia with isofluorane (Forane, Abbott ind.). Sixty rats were then immediately injected intraperitoneally (i.p.) with a dose of 10<sup>9</sup> colony-forming unit (CFU) of <italic>Escherichia coli (E. coli)</italic> diluted in 20 mL of sterile water to induce bacterial peritonitis as previously reported <xref rid="pone.0059692-Sanchez1" ref-type="bibr">[15]</xref>. Four hours later, a blood sample was taken from the saphena vein, centrifuged and stored at &#x02212;80&#x000b0;C for subsequent analysis.</p><p>Animals were then randomly allocated into four groups to receive: serum subcutaneously (s.c.) (Group I, n&#x0200a;=&#x0200a;15), ceftriaxone 100 mg/kg s.c. daily for 7 days beginning 4 hours after <italic>E. coli</italic> injection (Group II, n&#x0200a;=&#x0200a;15), anti-TNF-&#x003b1; mAb 15 mg/kg i.p. in a single dose (Centocor R&#x00026;D, Inc, Malvern, PA, USA) and ceftriaxone 100 mg/kg s.c. daily for 7 days (Group III, n&#x0200a;=&#x0200a;15) and monoclonal Antibody Anti-Tumour Necrosis Factor Alfa (anti-TNF-&#x003b1; mAb) 15 mg/kg i.p. in a single dose (Group IV, n&#x0200a;=&#x0200a;15). Survival was monitored daily for 7 days.</p></sec><sec id="s2d"><title>Laparotomy</title><p>Laparotomy was performed under anaesthesia with 10 mg/kg xylacine (Rompun, Bayer) and 50 mg/kg ketamine (ketolar, Parke-Dawis) in strictly sterile conditions in surviving rats 7 days after induction of peritonitis. In brief, abdominal fur was removed with a depilatory and the skin was sterilised with iodine. A short incision in the abdominal wall (3&#x02013;4 cm.) was performed and a sample of intraperitoneal fluid was obtained for bacterial culture. The abdomen was then opened via a 3 cm median incision and the remaining fluid was evacuated. If no free fluid was present, sterile swabs were passed over the parietal peritoneal surface and then plated. Samples of pleural fluid were also collected for microbiological study. The mesenteric lymph nodes from the ileo-cecal area were aseptically dissected, removed, weighed, and liquefied in sterile saline for bacterial culture. Blood was collected from the cava vein in a non-additive sterile interior vacutainer (Becton Dickinson Vacutainer Systems Eur., Meylan Cedex, France), centrifuged and stored to determine liver and renal function parameters and TNF-&#x003b1; and NOx levels. A sample of the liver was also obtained for histological evaluation. All samples were stored at &#x02013;80&#x000b0;C. Rats were then euthanized with intravenous sodium thiopentate (Penthotal, Abbott Laboratories).</p></sec><sec id="s2e"><title>Biochemical Analysis</title><p>Immunoassays for quantitative measurement of rat TNF-&#x003b1; in blood samples were performed using TNF-&#x003b1; Quantikine rat Immunoassays (R&#x00026;D Systems, Abingdon, UK) according to the manufacturer&#x02019;s instructions. All samples were tested in duplicate and read at 450 nm and 490 nm in a ThermoMax microplate reader (Molecular Devices, Sunnyvale, California, USA).</p><p>The sum of the NOx: nitrite (NO<sub>2</sub>
<sup>&#x02212;</sup>) and nitrate (NO<sub>3</sub>
<sup>&#x02212;</sup>) is widely used as an index of NO generation and expressed as NOx levels <xref rid="pone.0059692-Tsikas1" ref-type="bibr">[18]</xref>. NOx levels were calculated by measuring conversion of NO<sub>3</sub>
<sup>&#x02212;</sup> to NO<sub>2</sub>
<sup>&#x02212;</sup> by the enzyme nitrate reductase using an ELISA assay (R&#x00026;D Systems, Minneapolis, MN) based on the Griess reaction that absorbs visible light at 540 nm, and expressed as &#x000b5;mol/L. All samples were tested in duplicate, and values were corrected by running samples with culture media to assess background NOx levels.</p></sec><sec id="s2f"><title>Statistical Analysis of Experimental Data</title><p>Statistical analyses were performed with the SPSS statistical package (SPSS Inc. version 17.0, Chicago, Illinois, USA). All biochemical parameters are reported as mean &#x000b1; SD. Differences between groups were analysed using the non-parametric Mann-Whitney U-test. Fisher&#x02019;s exact test was used to compare mortality between groups. The Wilcoxon non-parametric test was used to compare variations of serum analytical parameters after inoculation with <italic>E. coli</italic>. A two-tailed p&#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec id="s3"><title>Results</title><p>Sixty rats with cirrhosis and without ascites, as demonstrated by a negative diagnostic paracentesis, were included and randomised. Forty-nine rats (81<bold>.</bold>7%) died during the study, mainly during the first 24 hours after <italic>E. coli</italic> injection. No rats died in the first 4 hours after intraperitoneal <italic>E. coli</italic> inoculation. <xref ref-type="fig" rid="pone-0059692-g001">Figure 1</xref> shows mortality during the week of the study. As detailed, all rats in groups I (placebo) and IV (treated with anti-TNF-&#x003b1; mAb alone) died during the study period. A significant reduction in mortality was observed in the overall group of cirrhotic rats treated with antibiotic with or without anti-TNF-&#x003b1; mAb (63.3%, groups II and III) as compared with animals not receiving antibiotics (100%, groups I and IV, p&#x0003c;0.001). Mortality in the group of animals treated with ceftriaxone alone (73.3%, group II) was lower than the corresponding value in groups I or IV, although differences did not reach statistical significance, probably due to the low number of animals tested. In contrast, infected cirrhotic rats treated with the combination of ceftriaxone plus anti-TNF-&#x003b1; mAb (group III) showed a significant reduction in mortality (53.3%) when compared to non-treated rats (group I, p&#x0003c;0.01) or to rats treated with anti-TNF-&#x003b1; mAb alone (group IV, p&#x0003c;0.01).</p><fig id="pone-0059692-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0059692.g001</object-id><label>Figure 1</label><caption><title>Mortality observed in rats with cirrhosis and induced bacterial peritonitis during one week after <italic>E. coli</italic> inoculation.</title><p>Group I: placebo (serum s.c.); Group II: ceftriaxone s.c.; Group III: anti-TNF-&#x003b1; mAb i.p.+ceftriaxone s.c.; Group IV: anti-TNF-&#x003b1; mAb i.p.; Groups I and IV (non-antibiotic treated rats) and Groups II and III (antibiotic treated rats).</p></caption><graphic xlink:href="pone.0059692.g001"/></fig><p>
<xref ref-type="table" rid="pone-0059692-t001">Table 1</xref> shows basal analytical parameters, including renal and liver function tests and serum TNF-&#x003b1; and NOx levels, obtained four hours after <italic>E. coli</italic> injection. All parameters were similar in all four groups of cirrhotic rats included in the study. When comparisons were established between non-surviving <italic>versus</italic> surviving animals, basal serum NOx was the only analytical parameter showing a significant increase in non-surviving rats (p&#x0003c;0.05).</p><table-wrap id="pone-0059692-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0059692.t001</object-id><label>Table 1</label><caption><title>Basal analytical parameters of the groups of cirrhotic rats with induced bacterial peritonitis.</title></caption><alternatives><graphic id="pone-0059692-t001-1" xlink:href="pone.0059692.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">GROUPS</td><td align="left" rowspan="1" colspan="1">I (n&#x0200a;=&#x0200a;15)</td><td align="left" rowspan="1" colspan="1">II (n&#x0200a;=&#x0200a;15)</td><td align="left" rowspan="1" colspan="1">III (n&#x0200a;=&#x0200a;15)</td><td align="left" rowspan="1" colspan="1">IV (n&#x0200a;=&#x0200a;15)</td><td align="left" rowspan="1" colspan="1">Non-surviving rats (n&#x0200a;=&#x0200a;49)</td><td align="left" rowspan="1" colspan="1">Surviving rats (n&#x0200a;=&#x0200a;11)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Urea (mM)</td><td align="left" rowspan="1" colspan="1">6,6&#x000b1;1,2</td><td align="left" rowspan="1" colspan="1">7,0&#x000b1;1,8</td><td align="left" rowspan="1" colspan="1">6,1&#x000b1;0,9</td><td align="left" rowspan="1" colspan="1">6,6&#x000b1;1,9</td><td align="left" rowspan="1" colspan="1">6,6&#x000b1;1,7</td><td align="left" rowspan="1" colspan="1">6,4&#x000b1;1,0</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (&#x000b5;M)</td><td align="left" rowspan="1" colspan="1">57,8&#x000b1;6,6</td><td align="left" rowspan="1" colspan="1">56,3&#x000b1;9,5</td><td align="left" rowspan="1" colspan="1">52,5&#x000b1;9,2</td><td align="left" rowspan="1" colspan="1">57,6&#x000b1;8,9</td><td align="left" rowspan="1" colspan="1">55,6&#x000b1;8,9</td><td align="left" rowspan="1" colspan="1">54,3&#x000b1;7,5</td></tr><tr><td align="left" rowspan="1" colspan="1">Bilirubine (&#x000b5;M)</td><td align="left" rowspan="1" colspan="1">11,9&#x000b1;9,5</td><td align="left" rowspan="1" colspan="1">12,5&#x000b1;7,2</td><td align="left" rowspan="1" colspan="1">17,1&#x000b1;10,1</td><td align="left" rowspan="1" colspan="1">13,6&#x000b1;10,2</td><td align="left" rowspan="1" colspan="1">15,1&#x000b1;9,6</td><td align="left" rowspan="1" colspan="1">12,9&#x000b1;7,7</td></tr><tr><td align="left" rowspan="1" colspan="1">AST (u/L)</td><td align="left" rowspan="1" colspan="1">1140&#x000b1;363</td><td align="left" rowspan="1" colspan="1">1020&#x000b1;585</td><td align="left" rowspan="1" colspan="1">1091&#x000b1;387</td><td align="left" rowspan="1" colspan="1">1014&#x000b1;616</td><td align="left" rowspan="1" colspan="1">1089&#x000b1;547</td><td align="left" rowspan="1" colspan="1">929&#x000b1;420</td></tr><tr><td align="left" rowspan="1" colspan="1">ALT (u/L)</td><td align="left" rowspan="1" colspan="1">622&#x000b1;316</td><td align="left" rowspan="1" colspan="1">693&#x000b1;482</td><td align="left" rowspan="1" colspan="1">608&#x000b1;263</td><td align="left" rowspan="1" colspan="1">640&#x000b1;509</td><td align="left" rowspan="1" colspan="1">650&#x000b1;438</td><td align="left" rowspan="1" colspan="1">640&#x000b1;349</td></tr><tr><td align="left" rowspan="1" colspan="1">GGT (u/L)</td><td align="left" rowspan="1" colspan="1">10,9&#x000b1;6,2</td><td align="left" rowspan="1" colspan="1">10,8&#x000b1;5,2</td><td align="left" rowspan="1" colspan="1">12,7&#x000b1;7,4</td><td align="left" rowspan="1" colspan="1">13,7&#x000b1;6,2</td><td align="left" rowspan="1" colspan="1">12,6&#x000b1;5,9</td><td align="left" rowspan="1" colspan="1">11,1&#x000b1;7,2</td></tr><tr><td align="left" rowspan="1" colspan="1">TNF-&#x003b1; (pg/mL)</td><td align="left" rowspan="1" colspan="1">176&#x000b1;100</td><td align="left" rowspan="1" colspan="1">163&#x000b1;96</td><td align="left" rowspan="1" colspan="1">204&#x000b1;118</td><td align="left" rowspan="1" colspan="1">207&#x000b1;137</td><td align="left" rowspan="1" colspan="1">198,6&#x000b1;117,7</td><td align="left" rowspan="1" colspan="1">167,6&#x000b1;101,4</td></tr><tr><td align="left" rowspan="1" colspan="1">NOx (nmol/mL)</td><td align="left" rowspan="1" colspan="1">107&#x000b1;30</td><td align="left" rowspan="1" colspan="1">98&#x000b1;39</td><td align="left" rowspan="1" colspan="1">121&#x000b1;46</td><td align="left" rowspan="1" colspan="1">129&#x000b1;89</td><td align="left" rowspan="1" colspan="1">125,4&#x000b1;62,0<xref ref-type="table-fn" rid="nt102">*</xref>
</td><td align="left" rowspan="1" colspan="1">84,9&#x000b1;26,9</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Samples of blood were obtained 4 hours after intraperitoneally administration of <italic>E. coli.</italic>
</p></fn><fn id="nt102"><label>*</label><p>p&#x0003c;0.05 respect to surviving rats.</p></fn></table-wrap-foot></table-wrap><p>Variations in renal and liver function tests and serum TNF-&#x003b1; and NOx levels were studied in surviving rats in samples obtained 4 hours after bacterial inoculation and at laparotomy. As detailed in <xref ref-type="table" rid="pone-0059692-t002">Table 2</xref>, a significant reduction in TNF-&#x003b1; serum levels was observed in these rats (groups II+III, p&#x0003c;0.05). This variation was even more remarkable in rats treated with ceftriaxone plus anti-TNF-&#x003b1; mAb (p&#x0003c;0.05). The decrease of serum TNF-&#x003b1; levels in rats treated with antibiotic alone, however, did not reach statistical significance. NOx levels showed a tendency to increase at laparotomy in comparison with baseline values in all surviving animals but this was only statistically significant in Groups II+III (p&#x0003c;0.05). Liver parameters also decreased significantly in these rats (p&#x0003c;0.01) and no variations in renal function were observed.</p><table-wrap id="pone-0059692-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0059692.t002</object-id><label>Table 2</label><caption><title>Variations in renal and liver function tests and serum TNF-&#x003b1; and NOx levels in surviving cirrhotic rats between the infection of <italic>E.coli</italic> and the laparotomy.</title></caption><alternatives><graphic id="pone-0059692-t002-2" xlink:href="pone.0059692.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">GROUPS</td><td align="left" rowspan="1" colspan="1">II (n&#x0200a;=&#x0200a;4 )</td><td align="left" rowspan="1" colspan="1">III (n&#x0200a;=&#x0200a;7 )</td><td align="left" rowspan="1" colspan="1">II+III (n&#x0200a;=&#x0200a;11 )</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Urea (mM)</td><td align="left" rowspan="1" colspan="1">6.7&#x000b1;1.0 &#x02192; 6.3&#x000b1;0.9</td><td align="left" rowspan="1" colspan="1">6.2&#x000b1;1.0 &#x02192; 6.1&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">6.4&#x000b1;1.0 &#x02192; 6.1&#x000b1;0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (&#x000b5;M)</td><td align="left" rowspan="1" colspan="1">51.5&#x000b1;4.1 &#x02192; 51.3&#x000b1;3.9</td><td align="left" rowspan="1" colspan="1">56.0&#x000b1;8.8 &#x02192; 56.3&#x000b1;7.6</td><td align="left" rowspan="1" colspan="1">54.3&#x000b1;7.5 &#x02192; 54.5&#x000b1;6.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Bilirubine (&#x000b5;M)</td><td align="left" rowspan="1" colspan="1">9.2&#x000b1;4.3 &#x02192; 1.5&#x000b1;0.6<xref ref-type="table-fn" rid="nt103">*</xref>
</td><td align="left" rowspan="1" colspan="1">15.0&#x000b1;8.7 &#x02192; 1.5&#x000b1;0.8<xref ref-type="table-fn" rid="nt103">*</xref>
</td><td align="left" rowspan="1" colspan="1">12.9&#x000b1;7.7 &#x02192; 1.5&#x000b1;0.7<xref ref-type="table-fn" rid="nt104">&#x02020;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">AST (u/L)</td><td align="left" rowspan="1" colspan="1">919&#x000b1;519 &#x02192; 174&#x000b1;116</td><td align="left" rowspan="1" colspan="1">936&#x000b1;401 &#x02192; 160&#x000b1;80<xref ref-type="table-fn" rid="nt103">*</xref>
</td><td align="left" rowspan="1" colspan="1">929&#x000b1;420 &#x02192; 165&#x000b1;89<xref ref-type="table-fn" rid="nt104">&#x02020;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">ALT (u/L)</td><td align="left" rowspan="1" colspan="1">558&#x000b1;336 &#x02192; 43&#x000b1;16</td><td align="left" rowspan="1" colspan="1">687&#x000b1;375 &#x02192; 46&#x000b1;30<xref ref-type="table-fn" rid="nt103">*</xref>
</td><td align="left" rowspan="1" colspan="1">640&#x000b1;349 &#x02192; 45&#x000b1;25<xref ref-type="table-fn" rid="nt104">&#x02020;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">GGT (u/L)</td><td align="left" rowspan="1" colspan="1">12.5&#x000b1;9.1 &#x02192; 3.6&#x000b1;4.7</td><td align="left" rowspan="1" colspan="1">10.3&#x000b1;6.6 &#x02192; 0.9&#x000b1;1.7<xref ref-type="table-fn" rid="nt103">*</xref>
</td><td align="left" rowspan="1" colspan="1">11.1&#x000b1;7.2 &#x02192; 1.7&#x000b1;2.9<xref ref-type="table-fn" rid="nt104">&#x02020;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TNF-&#x003b1; (pg/mL)</td><td align="left" rowspan="1" colspan="1">132&#x000b1;96 &#x02192; 98.4&#x000b1;60.4</td><td align="left" rowspan="1" colspan="1">189&#x000b1;118 &#x02192; 48.5&#x000b1;41.8<xref ref-type="table-fn" rid="nt103">*</xref>
</td><td align="left" rowspan="1" colspan="1">168.5&#x000b1;107 &#x02192; 66.6&#x000b1;52.7<xref ref-type="table-fn" rid="nt103">*</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NOx (nmol/mL)</td><td align="left" rowspan="1" colspan="1">74&#x000b1;39 &#x02192; 127.9&#x000b1;82.4</td><td align="left" rowspan="1" colspan="1">91&#x000b1;46 &#x02192; 139.6&#x000b1;68.5</td><td align="left" rowspan="1" colspan="1">85.5&#x000b1;42.5 &#x02192; 135.3&#x000b1;69.9<xref ref-type="table-fn" rid="nt103">*</xref>
</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label>*</label><p>p&#x0003c;0.05 respect to basal serum levels,</p></fn><fn id="nt104"><label>&#x02020;</label><p>p&#x0003c;0.01 respect to basal serum levels.</p></fn></table-wrap-foot></table-wrap><p>Laparotomy was performed on all surviving rats 7 days after intraperitoneal bacterial inoculation, and samples were cultured as described above. <italic>E. coli</italic> was isolated in pleural fluid in 1 animal from Group II, and when considering animals included in Group III, 1 animal showed an <italic>E. coli</italic> in peritoneal fluid, 1 rat presented <italic>E. coli</italic> and <italic>Enterococcus</italic> in mesenteric lymph nodes and a third animal had <italic>E. coli</italic> in the liver. The number of surviving rats with positive culture was higher in group II (3/4) than in group III (1/7), although values did not reach statistical significance (p&#x0200a;=&#x0200a;0.08).</p><p>Histological study of the liver was performed in all surviving rats and showed severe fibrosis in all cases.</p></sec><sec id="s4"><title>Discussion</title><p>To our knowledge, this is the first study to date to assess new therapeutic approaches to reduce mortality during episodes of bacterial peritonitis in cirrhotic rats. These rats develop SBP in the last phases of induction of cirrhosis, but animals are so sick at that time that they usually die during or immediately after the diagnostic paracentesis, becoming an inadequate model for the study of new therapeutic approaches. We developed a new model of induced bacterial peritonitis in rats with cirrhosis, with or without ascitic fluid, and reported mortality rates similar to those found in a clinical setting <xref rid="pone.0059692-Sanchez1" ref-type="bibr">[15]</xref>. This study represents the first application of this animal model to assess new therapeutic options to reduce mortality during episodes of induced bacterial peritonitis.</p><p>Our study investigated the effect of TNF-&#x003b1; blockade and/or antibiotics on the inflammatory response and mortality in a cirrhotic rat model with induced bacterial peritonitis. We here report evidences that modulation of inflammatory response, as represented by TNF-&#x003b1; blockade together with the usual third-generation cephalosporin-based therapy in animals with induced bacterial peritonitis, may represent a useful tool to increase survival compared to non-treated rats or treated only with TNF-&#x003b1; blockade. However, this benefit was not statistically significant compared to rats treated only with third-generation cephalosporin. In addition, despite a higher number of positive culture at laparotomy in surviving rats from group II (3/4) than in group III (1/7) (p&#x0200a;=&#x0200a;0.08), with the current data we can not speculate about a protective effect of TNF-&#x003b1; blockade with the combined treatment. Probably, additional studies including more animals are required to assess if the association of antibiotic therapy and TNF-&#x003b1; blockade might be a possible approach to reduce mortality in cirrhotic patients with spontaneous bacterial peritonitis.</p><p>As pointed out above, higher levels of NO and TNF-&#x003b1; at diagnosis of SBP and during SBP episodes predict complications such as renal insufficiency and survival <xref rid="pone.0059692-Navasa1" ref-type="bibr">[7]</xref>, <xref rid="pone.0059692-Such1" ref-type="bibr">[11]</xref>, <xref rid="pone.0059692-Byl1" ref-type="bibr">[19]</xref>. Recent findings from our group may offer a clue to explain the maintained inflammatory reaction in SBP. When studying sequential samples of blood from SBP patients under antibiotic therapy, we observed the maintenance of molecular evidence of BT as demonstrated by the presence of bacterial genomic fragments (bacterial DNA) in blood and found that levels kept a direct and significant relation with proinflammatory cytokines and NO <xref rid="pone.0059692-Frances1" ref-type="bibr">[12]</xref>. However, in rats, TNF-&#x003b1; blockade appears to blunt hemodynamic disturbances in a model of portal hypertension <xref rid="pone.0059692-LopezTalavera1" ref-type="bibr">[13]</xref>, and reduce episodes of BT in a model of cirrhosis <xref rid="pone.0059692-Frances2" ref-type="bibr">[14]</xref>. These data suggest that modulation of the inflammatory response might improve survival, supporting our hypothesis that the use of a selective mAb against TNF-&#x003b1; together with ceftriaxone would decrease mortality in an intraperitoneal infection episode. Since TNF-&#x003b1; is part of the normal immune response against bacterial infections, it is necessary to investigate whether the administration of anti-TNF-&#x003b1; mAb might result in an increased risk of bacterial superinfections. However, in the present study we did not observe superinfections in surviving rats treated with antibiotics and anti-TNF-&#x003b1; mAb.</p><p>There were two main analytical findings when comparing samples obtained immediately after i.p. administration of <italic>E. coli</italic> and at laparotomy in surviving rats: first, baseline NOx was the only parameter to show statistically significant differences between surviving and dying rats (<xref ref-type="table" rid="pone-0059692-t001">Table 1</xref>). This information is similar to that reported in patients with SBP <xref rid="pone.0059692-Such1" ref-type="bibr">[11]</xref>, and may be related to repeated episodes of BT and stimulation of the immune response prior to i.p. injection with <italic>E. coli</italic>. Indeed, bacteria components such as lipopolysacharide or DNA stimulate the immune response through joining toll-like receptors 4 and 9, respectively <xref rid="pone.0059692-Beutler1" ref-type="bibr">[20]</xref>, <xref rid="pone.0059692-Frances3" ref-type="bibr">[21]</xref>, and it is likely that higher NOx levels will correlate with more severe haemodynamic disturbances in this model.</p><p>Second, TNF-&#x003b1; levels decreased significantly in surviving animals when receiving ceftriaxone alone or in combination with mAb, although values only reached significance in the combination therapy arm. This seems logical when considering the specificity of anti-TNF-&#x003b1; mAb used in this investigation. No differences in the rate of BT were observed when comparing animals included in Groups II or III. These results are similar to others previously reported by our group <xref rid="pone.0059692-Frances2" ref-type="bibr">[14]</xref> that showed that anti-TNF-&#x003b1; mAb in non-infected rats with cirrhosis does not increase the likelihood of developing infections. In this investigation, however, rats were infected, and the trend towards an increased persistence of bacteria in mesenteric lymph nodes in animals receiving the combination therapy may point to a decreased ability to fight against infection once it is established. Caution should therefore be recommended when considering the immune modulation with administration of anti-TNF-&#x003b1; mAb in an active infection setting.</p><p>TNF-&#x003b1; blockade may be also achieved by several non-monoclonal related molecules. Xanthine derivatives such as pentoxifylline <xref rid="pone.0059692-Marques1" ref-type="bibr">[22]</xref> or serotonin 5-hydroxytryptamine (2A) receptor agonists such as 2,5-dimethoxy-4-iodoamphetamine <xref rid="pone.0059692-Yu1" ref-type="bibr">[23]</xref> are potent TNF-&#x003b1; inhibitors that might be use to confirm presented data. In addition, the use of these molecules would avoid the formation of anti-drug antibodies.</p><p>In conclusion, the administration of ceftriaxone and anti-TNF-&#x003b1; mAb decreases serum TNF-&#x003b1; levels. However, in the present study we did not observe significant differences on survival in cirrhotic rats with induced bacterial peritonitis treated with antibiotics with or without anti-TNF-&#x003b1; mAb. Additional studies including more animals are required to assess if the association of antibiotic therapy and TNF-&#x003b1; blockade might be a possible approach to reduce mortality in cirrhotic patients with bacterial peritonitis, before this therapeutic combination can be recommended. This animal model may represent a useful tool to assess the efficacy of new therapies in these patients.</p></sec></body><back><ack><p>CIBERehd is funded by the Instituto de Salud Carlos III Centro de Investigaci&#x000f3;n Biom&#x000e9;dica en Red de Enfermedades Hep&#x000e1;ticas y Digestivas, CIBERehd (Madrid, Spain). We thank Carolyn Newey for English language revision.</p></ack><ref-list><title>References</title><ref id="pone.0059692-Guarner1"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Guarner</surname><given-names>C</given-names></name>, <name><surname>Runyon</surname><given-names>BA</given-names></name> (<year>1995</year>) <article-title>Spontaneous bacterial peritonitis: pathogenesis, diagnosis, and management</article-title>. <source>Gastroenterologist</source>
<volume>3</volume>: <fpage>311</fpage>&#x02013;<lpage>328</lpage>.<pub-id pub-id-type="pmid">8775093</pub-id></mixed-citation></ref><ref id="pone.0059692-Rimola1"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Rimola</surname><given-names>A</given-names></name>, <name><surname>Garcia-Tsao</surname><given-names>G</given-names></name>, <name><surname>Navasa</surname><given-names>M</given-names></name>, <name><surname>Piddock</surname><given-names>LJ</given-names></name>, <name><surname>Planas</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2000</year>) <article-title>Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club</article-title>. <source>J Hepatol</source>
<volume>32</volume>: <fpage>142</fpage>&#x02013;<lpage>153</lpage>.<pub-id pub-id-type="pmid">10673079</pub-id></mixed-citation></ref><ref id="pone.0059692-Runyon1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Runyon</surname><given-names>BA</given-names></name> (<year>2004</year>) <article-title>Management of adult patients with ascites due to cirrhosis</article-title>. <source>Hepatology</source>
<volume>39</volume>: <fpage>841</fpage>&#x02013;<lpage>856</lpage>.<pub-id pub-id-type="pmid">14999706</pub-id></mixed-citation></ref><ref id="pone.0059692-Felisart1"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Felisart</surname><given-names>J</given-names></name>, <name><surname>Rimola</surname><given-names>A</given-names></name>, <name><surname>Arroyo</surname><given-names>V</given-names></name>, <name><surname>Perez Ayuso</surname><given-names>RM</given-names></name>, <name><surname>Quintero</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>1985</year>) <article-title>Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections</article-title>. <source>Hepatology</source>
<volume>5</volume>: <fpage>457</fpage>&#x02013;<lpage>462</lpage>.<pub-id pub-id-type="pmid">3888810</pub-id></mixed-citation></ref><ref id="pone.0059692-Follo1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Follo</surname><given-names>A</given-names></name>, <name><surname>Llovet</surname><given-names>JM</given-names></name>, <name><surname>Navasa</surname><given-names>M</given-names></name>, <name><surname>Planas</surname><given-names>R</given-names></name>, <name><surname>Forns</surname><given-names>X</given-names></name>, <etal>et al</etal> (<year>1994</year>) <article-title>Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis</article-title>. <source>Hepatology</source>
<volume>20</volume>: <fpage>1495</fpage>&#x02013;<lpage>1501</lpage>.<pub-id pub-id-type="pmid">7982650</pub-id></mixed-citation></ref><ref id="pone.0059692-Sort1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Sort</surname><given-names>P</given-names></name>, <name><surname>Navasa</surname><given-names>M</given-names></name>, <name><surname>Arroyo</surname><given-names>V</given-names></name>, <name><surname>Aldeguer</surname><given-names>X</given-names></name>, <name><surname>Planas</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis</article-title>. <source>N Engl J Med</source>
<volume>341</volume>: <fpage>403</fpage>&#x02013;<lpage>409</lpage>.<pub-id pub-id-type="pmid">10432325</pub-id></mixed-citation></ref><ref id="pone.0059692-Navasa1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Navasa</surname><given-names>M</given-names></name>, <name><surname>Follo</surname><given-names>A</given-names></name>, <name><surname>Filella</surname><given-names>X</given-names></name>, <name><surname>Jimenez</surname><given-names>W</given-names></name>, <name><surname>Francitorra</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>1998</year>) <article-title>Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality</article-title>. <source>Hepatology</source>
<volume>27</volume>: <fpage>1227</fpage>&#x02013;<lpage>1232</lpage>.<pub-id pub-id-type="pmid">9581675</pub-id></mixed-citation></ref><ref id="pone.0059692-GarciaTsao1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Garcia-Tsao</surname><given-names>G</given-names></name>, <name><surname>Angulo</surname><given-names>P</given-names></name>, <name><surname>Garcia</surname><given-names>JC</given-names></name>, <name><surname>Groszmann</surname><given-names>RJ</given-names></name>, <name><surname>Cadelina</surname><given-names>GW</given-names></name> (<year>1998</year>) <article-title>The diagnostic and predictive value of ascites nitric oxide levels in patients with spontaneous bacterial peritonitis</article-title>. <source>Hepatology</source>
<volume>28</volume>: <fpage>17</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">9657091</pub-id></mixed-citation></ref><ref id="pone.0059692-Bories1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Bories</surname><given-names>PN</given-names></name>, <name><surname>Campillo</surname><given-names>B</given-names></name>, <name><surname>Azaou</surname><given-names>L</given-names></name>, <name><surname>Scherman</surname><given-names>E</given-names></name> (<year>1997</year>) <article-title>Long-lasting NO overproduction in cirrhotic patients with spontaneous bacterial peritonitis</article-title>. <source>Hepatology</source>
<volume>25</volume>: <fpage>1328</fpage>&#x02013;<lpage>1333</lpage>.<pub-id pub-id-type="pmid">9185747</pub-id></mixed-citation></ref><ref id="pone.0059692-Genesca1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Genesca</surname><given-names>J</given-names></name>, <name><surname>Gonzalez</surname><given-names>A</given-names></name>, <name><surname>Segura</surname><given-names>R</given-names></name>, <name><surname>Catalan</surname><given-names>R</given-names></name>, <name><surname>Marti</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis</article-title>. <source>Am J Gastroenterol</source>
<volume>94</volume>: <fpage>169</fpage>&#x02013;<lpage>177</lpage>.<pub-id pub-id-type="pmid">9934750</pub-id></mixed-citation></ref><ref id="pone.0059692-Such1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Such</surname><given-names>J</given-names></name>, <name><surname>Hillebrand</surname><given-names>DJ</given-names></name>, <name><surname>Guarner</surname><given-names>C</given-names></name>, <name><surname>Berk</surname><given-names>L</given-names></name>, <name><surname>Zapater</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Nitric oxide in ascitic fluid is an independent predictor of the development of renal impairment in patients with cirrhosis and spontaneous bacterial peritonitis</article-title>. <source>Eur J Gastroenterol Hepatol</source>
<volume>16</volume>: <fpage>571</fpage>&#x02013;<lpage>577</lpage>.<pub-id pub-id-type="pmid">15167159</pub-id></mixed-citation></ref><ref id="pone.0059692-Frances1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Frances</surname><given-names>R</given-names></name>, <name><surname>Zapater</surname><given-names>P</given-names></name>, <name><surname>Gonzalez-Navajas</surname><given-names>JM</given-names></name>, <name><surname>Munoz</surname><given-names>C</given-names></name>, <name><surname>Cano</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis</article-title>. <source>Hepatology</source>
<volume>47</volume>: <fpage>978</fpage>&#x02013;<lpage>985</lpage>.<pub-id pub-id-type="pmid">18306221</pub-id></mixed-citation></ref><ref id="pone.0059692-LopezTalavera1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Lopez-Talavera</surname><given-names>JC</given-names></name>, <name><surname>Merrill</surname><given-names>WW</given-names></name>, <name><surname>Groszmann</surname><given-names>RJ</given-names></name> (<year>1995</year>) <article-title>Tumor necrosis factor a: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats</article-title>. <source>Gastroenterology</source>
<volume>108</volume>: <fpage>761</fpage>&#x02013;<lpage>767</lpage>.<pub-id pub-id-type="pmid">7875478</pub-id></mixed-citation></ref><ref id="pone.0059692-Frances2"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Frances</surname><given-names>R</given-names></name>, <name><surname>Chiva</surname><given-names>M</given-names></name>, <name><surname>Sanchez</surname><given-names>E</given-names></name>, <name><surname>Gonzalez-Navajas</surname><given-names>JM</given-names></name>, <name><surname>Llovet</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Bacterial translocation is downregulated by anti-TNF-alpha monoclonal antibody administration in rats with cirrhosis and ascites</article-title>. <source>J Hepatol</source>
<volume>46</volume>: <fpage>797</fpage>&#x02013;<lpage>803</lpage>.<pub-id pub-id-type="pmid">17321632</pub-id></mixed-citation></ref><ref id="pone.0059692-Sanchez1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Sanchez</surname><given-names>E</given-names></name>, <name><surname>Such</surname><given-names>J</given-names></name>, <name><surname>Chiva</surname><given-names>MT</given-names></name>, <name><surname>Soriano</surname><given-names>G</given-names></name>, <name><surname>Llovet</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Development of an experimental model of induced bacterial peritonitis in cirrhotic rats with or without ascites</article-title>. <source>Am J Gastroenterol</source>
<volume>102</volume>: <fpage>1230</fpage>&#x02013;<lpage>1236</lpage>.<pub-id pub-id-type="pmid">17531011</pub-id></mixed-citation></ref><ref id="pone.0059692-Runyon2"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Runyon</surname><given-names>BA</given-names></name>, <name><surname>Sugano</surname><given-names>S</given-names></name>, <name><surname>Kanel</surname><given-names>G</given-names></name>, <name><surname>Mellencamp</surname><given-names>MA</given-names></name> (<year>1991</year>) <article-title>A rodent model of cirrhosis, ascites, and bacterial peritonitis</article-title>. <source>Gastroenterology</source>
<volume>100</volume>: <fpage>489</fpage>&#x02013;<lpage>493</lpage>.<pub-id pub-id-type="pmid">1985046</pub-id></mixed-citation></ref><ref id="pone.0059692-Runyon3"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Runyon</surname><given-names>BA</given-names></name>, <name><surname>Squier</surname><given-names>S</given-names></name>, <name><surname>Borzio</surname><given-names>M</given-names></name> (<year>1994</year>) <article-title>Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis</article-title>. <source>J Hepatol</source>
<volume>21</volume>: <fpage>792</fpage>&#x02013;<lpage>796</lpage>.<pub-id pub-id-type="pmid">7890896</pub-id></mixed-citation></ref><ref id="pone.0059692-Tsikas1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Tsikas</surname><given-names>D</given-names></name> (<year>2005</year>) <article-title>Methods of quantitative analysis of the nitric oxide metabolites nitrite and nitrate in human biological fluids</article-title>. <source>Free Radic Res</source>
<volume>39</volume>: <fpage>797</fpage>&#x02013;<lpage>815</lpage>.<pub-id pub-id-type="pmid">16036360</pub-id></mixed-citation></ref><ref id="pone.0059692-Byl1"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Byl</surname><given-names>B</given-names></name>, <name><surname>Roucloux</surname><given-names>I</given-names></name>, <name><surname>Crusiaux</surname><given-names>A</given-names></name>, <name><surname>Dupont</surname><given-names>E</given-names></name>, <name><surname>Deviere</surname><given-names>J</given-names></name> (<year>1993</year>) <article-title>Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patients</article-title>. <source>Gastroenterology</source>
<volume>104</volume>: <fpage>1492</fpage>&#x02013;<lpage>1497</lpage>.<pub-id pub-id-type="pmid">8482461</pub-id></mixed-citation></ref><ref id="pone.0059692-Beutler1"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Beutler</surname><given-names>B</given-names></name> (<year>2000</year>) <article-title>Tlr4: central component of the sole mammalian LPS sensor</article-title>. <source>Curr Opin Immunol</source>
<volume>12</volume>: <fpage>20</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">10679411</pub-id></mixed-citation></ref><ref id="pone.0059692-Frances3"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Frances</surname><given-names>R</given-names></name>, <name><surname>Munoz</surname><given-names>C</given-names></name>, <name><surname>Zapater</surname><given-names>P</given-names></name>, <name><surname>Uceda</surname><given-names>F</given-names></name>, <name><surname>Gascon</surname><given-names>I</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites</article-title>. <source>Gut</source>
<volume>53</volume>: <fpage>860</fpage>&#x02013;<lpage>864</lpage>.<pub-id pub-id-type="pmid">15138214</pub-id></mixed-citation></ref><ref id="pone.0059692-Marques1"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Marques</surname><given-names>LJ</given-names></name>, <name><surname>Zheng</surname><given-names>L</given-names></name>, <name><surname>Poulakis</surname><given-names>N</given-names></name>, <name><surname>Guzman</surname><given-names>J</given-names></name>, <name><surname>Costabel</surname><given-names>U</given-names></name> (<year>1999</year>) <article-title>Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med</article-title>. <volume>159(2)</volume>: <fpage>508</fpage>&#x02013;<lpage>511</lpage>.</mixed-citation></ref><ref id="pone.0059692-Yu1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Yu</surname><given-names>B</given-names></name>, <name><surname>Becnel</surname><given-names>J</given-names></name>, <name><surname>Zerfaoui</surname><given-names>M</given-names></name>, <name><surname>Rohatgi</surname><given-names>R</given-names></name>, <name><surname>Boulares</surname><given-names>AH</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Serotonin 5-hydroxytryptamine (2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency. J Pharmacol Exp Ther</article-title>. <volume>327(2)</volume>: <fpage>316</fpage>&#x02013;<lpage>323</lpage>.</mixed-citation></ref></ref-list></back></article>